Stock SEEL SEELOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Seelos Therapeutics, Inc.

Equities

SEEL

US81577F2083

Real-time Estimate Cboe BZX
Other stock markets
 02:32:26 2024-05-06 pm EDT 		5-day change 1st Jan Change
0.317 USD -6.57% Intraday chart for Seelos Therapeutics, Inc. +11.95% -77.42%
Apr. 29 Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors CI
Mar. 19 Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating
MT
Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy
MT
Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight
MT
Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates
MT
US Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decision
MT
Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating
MT
Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating
MT
B. Riley Lowers Seelos Therapeutics' PT to $4 from $6, Conservatively Adjusts for Higher Cost of Capital to Support Higher Operating Expenses Ramp; Keeps Buy Rating
MT
Cantor Fitzgerald Adjusts Seelos Therapeutics' Price Target to $3 from $5, Maintains Overweight Rating
MT
Cantor Fitzgerald Adjusts Seelos Therapeutics' Price Target to $3 From $5, Reiterates Overweight Rating
MT
B. Riley Lowers Seelos Therapeutics' Price Target to $6 from $11 After Revising Cost Capital Assumptions, Keeps Buy Rating
MT
SEELOS THERAPEUTICS : Roth Capital Upgrades Seelos Therapeutics to Buy from Neutral, Adjusts Price Target to $8 from $2.50
MT
SEELOS THERAPEUTICS : B. Riley Lowers Seelos Therapeutics' PT to $11 from $15, Keeps Buy Rating
MT
SEELOS THERAPEUTICS : Roth Capital Adjusts Price Target on Seelos Therapeutics to $2.50 From $4, Maintains Neutral Rating
MT
SEELOS THERAPEUTICS : Guggenheim Starts Seelos Therapeutics at Buy With $8 Price Target
MT
SEELOS THERAPEUTICS : Cantor Fitzgerald Initiates Coverage on Seelos Therapeutics With Overweight Rating, $10 Price Target
MT
SEELOS THERAPEUTICS : B. Riley Starts Seelos Therapeutics at Buy with $15 PT, Says High-Value Neuroscience Pipeline Coming Together
MT
SEELOS THERAPEUTICS : BTIG Starts Seelos Therapeutics at Buy with Street-High $14 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SEEL Stock
  4. News Seelos Therapeutics, Inc.
  5. Analyst Reco.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW